Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival
for younger patients over the last several decades has improved nearly sixfold with the …

In spite of consistent progress at the level of basic research and of clinical treatment, acute
myeloid leukemia (AML) still represents an unmet clinical need for adult and pediatric …

Introduction The emergence of resistance to the highly successful BCL2-directed therapy is
a major unmet need in acute myeloid leukemia (AML), an aggressive malignancy with poor …

The choice between an older matched sibling donor (MSD) and a younger matched
unrelated donor (MUD) in allogeneic hematopoietic cell transplantation (HCT) remains a …

The pivotal RATIFY study demonstrated midostaurin (50 mg twice daily) with standard
chemotherapy significantly reduced mortality in adult patients (< 60 years) with newly …

Sanguinarine (1) is a natural product with significant pharmacological effects. However, the
application of sanguinarine has been limited due to its toxic side effects and a lack of clarity …

Simple Summary Cytological approaches have long been used in the diagnosis, prognosis,
and management of acute myeloid leukemia (AML) and myelodysplastic neoplasms …

There is an urgent need for the identification as well as clinicopathological and functional
characterization of potent prognostic biomarkers and therapeutic targets in acute myeloid …

Despite advancements, acute myeloid leukemia (AML) remains unconquered by current
therapies. Evidence of immune evasion during AML progression, such as HLA loss and T …

Acute leukemias are complex diseases to treat and have a high mortality rate. The
immunosuppression caused by chemotherapy also causes the patient to become …